P/E ratio for Precigen (PGEN)
P/E ratio as of April 2024 (TTM): 9.40
According to Precigen's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 9.4. At the end of 2022 the company had a P/E ratio of 10.9.
P/E ratio history for Precigen from 2013 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 10.9 | -237.54% |
| 2021 | -7.89 | -21.06% |
| 2020 | -10.0 | 281.39% |
| 2019 | -2.62 | 56.36% |
| 2018 | -1.68 | -85.73% |
| 2017 | -11.8 | -23.57% |
| 2016 | -15.4 | -62.76% |
| 2015 | -41.3 | 24.52% |
| 2014 | -33.2 | 1289.03% |
| 2013 | -2.39 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Organovo ONVO | -0.4854 | -105.16% | 🇺🇸 USA |
 Orchard Therapeutics
ORTX | -2.69 | -128.65% | 🇬🇧 UK |
 Novavax NVAX | -0.5685 | -106.05% | 🇺🇸 USA |
 Novocure
NVCR | -6.78 | -172.18% | Jersey |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.